Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20126230 | 0.89 | CACNA2D1 (0.37) | HRH3CYP2C9KCNH2CYP3A4MAPT | |
| SCHEMBL20126186 | 0.82 | NQO1 (0.40) | HRH3CYP2C9KCNH2CYP3A4MAPT | |
| SCHEMBL20126118 | 0.78 | MAPT (0.35) | HRH3KCNH2MAPTALDH1A1KDM4E | |
| SCHEMBL20126308 | 0.75 | NQO1 (0.40) | MAPTALDH1A1KDM4EGAAMAPK1 | |
| SCHEMBL13023407 | 0.71 | ALOX5 (0.39) | HRH3CYP2C9KCNH2CYP3A4MAPT | |
| SCHEMBL9586183 | 0.71 | NQO1 (0.61) | HRH3CYP2C9KCNH2CYP3A4MAPT | |
| SCHEMBL20118136 | 0.70 | ESR2 (0.49) | HRH3MAPTALDH1A1DRD2CACNA2D1 | |
| SCHEMBL19053611 | 0.70 | NQO1 (0.47) | HRH3CYP2C9KCNH2CYP3A4MAPT | |
| SCHEMBL13579427 | 0.70 | NQO1 (0.35) | HRH3CYP2C9KCNH2CYP3A4MAPT | |
| SCHEMBL20129351 | 0.70 | MAPT (0.40) | HRH3CYP2C9KCNH2CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127654-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-10 | — | — | US | disclosed |
| US-20180127654-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127654-A1 | PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | DRD1, PLD1, DRD2 | HRH3 85/4885CYP2C9 348/4885KCNH2 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.